| Name | Title | Contact Details |
|---|---|---|
Elias Nyankojo |
Vice President,Chief Information Security Officer | Profile |
Molecular Templates is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers. Our Engineered Toxin Bodies (ETBs) platform represent a new class of targeted biologic therapies that possess unique biological properties.
Regional Clinical Research is a Endicott, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity`s greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio`s technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.
A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.